Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients

No difference in sustained virological response 12 weeks after completing treatment was noted in this prospective observational cohort study of 76 patients on treatment with either sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir (95.7% v 96.7% respectively, P=0.7).

European Journal of Hospital Pharmacy